Eli Lilly’s

Eli Lilly has reported that its interleukin-13 (IL-13) inhibitor Ebglyss (lebrikizumab-lbkz) showed sustained skin clearance for moderate-to-severe atopic dermatitis (AD) in the Phase III ADjoin extension trial. The study highlighted Ebglyss' ability to deliver durable disease control.

In this trial, the therapy was administered as a single injection of 250mg once every eight weeks, versus once every four weeks. The therapy particularly blocks IL-13 signalling, a principal contributor to AD’s type-2 inflammation cycle that causes infection, thickening, itching, and skin barrier damage.

In the ADjoin extension study, every-other-month dosing achieved similar efficacy: 79% of participants maintained or achieved eczema area and severity index (EASI) 75 versus 86% with monthly dosing. Furthermore, 62% maintained or achieved IGA 0,1 compared with 73% on monthly schedule.

Lilly submitted these findings to the US Food and Drug Administration (FDA) for a label update and is currently investigating a 12-week, 500mg maintenance schedule.

Lilly immunology development senior vice-president Mark Genovese said: “Lilly continues to optimise dosing frequency to push boundaries that redefine the patient experience. These new findings build on Ebglyss’ proven efficacy and demonstrate the potential for disease control with even less frequent dosing. We are pursuing an every-eight-week maintenance dosing label update with the FDA. We are also testing every-12-week maintenance dosing with our partner Almirall, as well as potentially exploring every-12-week dosing in independent Lilly-led studies.”

The data supplement strong long-term results for Ebglyss, including efficacy across diverse skin tones. In October 2024, Eli Lilly’s Ebglyss demonstrated improvement in skin condition and itch relief in patients with moderate-to-severe AD, according to new results from the Phase IIIb ADapt study.